Gene-expression profiling of localized prostate cancer: still miles to go before we sleep.

about

Gene-expression profiling of localized prostate cancer: still miles to go before we sleep.

Item

http://www.wikidata.org/entity/Q44062050

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Gene-expression profiling of l ...... l miles to go before we sleep.

@en

Gene-expression profiling of l ...... l miles to go before we sleep.

@nl

type

Item

label

Gene-expression profiling of l ...... l miles to go before we sleep.

@en

Gene-expression profiling of l ...... l miles to go before we sleep.

@nl

prefLabel

Gene-expression profiling of l ...... l miles to go before we sleep.

@en

Gene-expression profiling of l ...... l miles to go before we sleep.

@nl

P1476

Gene-expression profiling of l ...... l miles to go before we sleep.

@en

P2093

Mark Garzotto

http://www.w3.org/2001/XMLSchema#string

Ryan P Kopp

http://www.w3.org/2001/XMLSchema#string

P2860

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Integrative clinical genomics of advanced prostate cancer.

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study

Cancer Incidence in BRCA1 mutation carriers.

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort

Ten years of next-generation sequencing technology.

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.

P304

273-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/FON.15.316

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26814711

http://www.w3.org/2001/XMLSchema#string